Most Read Articles
Roshini Claire Anthony, 10 Jul 2019

Women who receive a single dose of amoxicillin and clavulanic acid within 6 hours of operative vaginal delivery could significantly reduce their postpartum infection risk, according to the UK-based ANODE* trial.

17 Jun 2019
Podcast: Dr Sara Hurvitz highlights that the addition of ribociclib to endocrine therapy improved overall survival in premenopausal women with HR+, HER2- advanced breast cancer, according to the MONALEESA-7 trial.
Audrey Abella, 05 Jul 2018
The addition of the sodium-glucose cotransporter-2 inhibitor ertugliflozin to metformin improved glycaemic control, body weight, and blood pressure (BP) in patients with inadequately controlled type 2 diabetes (T2D), according to the results of the VERTIS MET* trial presented at ADA 2018.
17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.

Hepatitis C presents increased risk of metabolic syndrome

03 Oct 2018

It appears that the risk of metabolic syndrome (MetS) is heightened in the presence of hepatitis C virus (HCV) infection but is reduced only in lean patients with hepatitis B virus (HBV) infection, a study has found.

The study included 180,359 individuals aged 40 years who underwent a series of community‐based health screenings. Of these, 18,726 (10.4 percent) had HBV, 13,428 (7.4 percent) had HCV and 1,337 (0.7 percent) had HBV plus HCV (B+C). The remaining 146,868 (81.5 percent) were non‐HBV/non‐HCV controls (NBNC).

MetS had a prevalence rate of 30.1 percent overall. For the subgroups, prevalence rates were 25.2 percent in patients with HBV, 31.5 percent in those with HCV, 28.9 percent in those with B+C and 30.7 percent in NBNC controls (p<0.001).

Among 54,361 individuals with MetS, body mass index status was lean in 18.8 percent, overweight in 35.4 percent and obese in 45.8 percent. Compared with obese individuals with MetS, their lean counterparts were older, had more diabetes and had higher metabolic component levels, but had lower alanine transaminase and aspartate transaminase‐platelet ratio index levels.

Logistic regression analysis showed a significant, positive association between HCV infection and MetS (p<0.001). On the other hand, HBV infection was inversely associated with MetS only among lean individuals (p=0.002) but not among the general population.

Researchers pointed out that older age and female gender are the two most important factors contributing to an increased risk of MetS, which is highly prevalent in postmenopausal women.

Additionally, the current study demonstrates that lean MetS, similar to lean nonalcoholic fatty liver disease, may exhibit more manifestations of extrahepatic diseases but not increase the risk of hepatic severity compared with obese MetS, they said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 10 Jul 2019

Women who receive a single dose of amoxicillin and clavulanic acid within 6 hours of operative vaginal delivery could significantly reduce their postpartum infection risk, according to the UK-based ANODE* trial.

17 Jun 2019
Podcast: Dr Sara Hurvitz highlights that the addition of ribociclib to endocrine therapy improved overall survival in premenopausal women with HR+, HER2- advanced breast cancer, according to the MONALEESA-7 trial.
Audrey Abella, 05 Jul 2018
The addition of the sodium-glucose cotransporter-2 inhibitor ertugliflozin to metformin improved glycaemic control, body weight, and blood pressure (BP) in patients with inadequately controlled type 2 diabetes (T2D), according to the results of the VERTIS MET* trial presented at ADA 2018.
17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.